Effects of teriparatide retreatment in osteoporotic men and women.
Joel S Finkelstein, Jason J Wyland, Benjamin Z Leder...
https://pubmed.ncbi.nlm.nih.gov/19401368Completed
Led by Massachusetts General Hospital · Updated on 2013-12-09
176
Participants Needed
1
Research Sites
8 weeks
Total Duration
M
Massachusetts General Hospital
Lead Sponsor
N
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Collaborating Sponsor
This study looks at the effects of two medications, alendronate and parathyroid hormone, on bone mass and on bone formation and bone breakdown in women with osteoporosis. We will randomly select postmenopausal women who have osteoporosis to receive laboratory-produced human parathyroid hormone (hPTH), or alendronate, or both for 2.5 years. Study participants will return to the study center periodically to have their bone mass measured and to give blood and urine samples for tests of bone formation and breakdown and for other laboratory tests. Those who complete the study are eligible for one or two 12 month extension studies.
CONDITIONS
Alendronate and/or Parathyroid Hormone for Osteoporosis
You may qualify if you...
You will not qualify if you...
Total: 1 location
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Status Unknown
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Joel S Finkelstein, Jason J Wyland, Benjamin Z Leder...
https://pubmed.ncbi.nlm.nih.gov/19401368